Webinar on-demand: Scalable Logistics for Cell and Gene Therapies

By Simon Ellison |

Using case studies and then applying academic principles, this webinar looks at the value of planning logistics early in the development of cell and gene therapies.
More traditional therapies have elongated clinical trials and established supply chains. However cell and gene therapies are moving from Phase I to marketing authorization application in 5 years, and have complicated temperature-critical, time-sensitive logistics requirements.

It is valuable, therefore, to have a vision for the commercial supply chain and use the clinical trial process to build, test and optimize the logistics platform ready for commercial launch.

Learning Outcomes

The value of planning early
The impact of poor logistics on a therapy's ability to treat patients
The complexity of cell and gene therapy supply chains
How to develop a logistics platform that can support clinical trials but be able to grow into commercial scale

In Collaboration with




Joshua Anderson
Senior Manager, Clinical Supply Operations           
  Simon Ellison
Cell and Gene Therapy Service Director                
World Courier
  Ryan McCoy
Lead Technical Scientist                                      
Cell and Gene Therapy Catapult

About the Author

A portrait of Simon Eliison.

Simon Ellison

Cell and Gene Therapy Service Director 
World Courier
Simon is the Cell and Gene Therapy Service Director at World Courier.  His role is to develop a portfolio of global logistic and supporting service strategies that take the advanced therapy industry forwards. Whilst at the Cell and Gene Therapy Catapult he identified the need for, and built the Seamless Freight portfolio.  He also helped develop the commercial operating model for the Catapult Manufacturing Centre that resulted in the first collaborators entering, and the start of a cluster forming around this unique facility. Prior to this Simon was the Head of Commercial at NHS Blood and Transplant (NHSBT) where he merged the needs of the industry with NHSBTs manufacturing and supply chain capability. This enabled multiple UK and international organisations to move their therapies forwards.
View Bio